세계의 게실염 시장 보고서(2025년)
Diverticulitis Disease Global Market Report 2025
상품코드 : 1824647
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

게실염 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.5%를 나타내 29억 1,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 대장 내시경 검사 및 내시경 검사, 인지도 향상, 낮은 침습 처치 및 맞춤형 의료로 인한 것입니다. 예측 기간의 주요 동향으로는 예방 조치, 진단 도구 강화, 공동 케어 모델, 건강 관리 정책 변화 등이 있습니다.

향후 5년간의 성장률 9.5%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 이탈리아와 크로아티아에서 수입되는 복강경 수술용 스테이플러와 정맥내 항생제의 가격을 상승시켜 개입 지연과 대장 항문 수술 비용 증가를 초래하여 미국의 소화기 의료에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

흡연 중독 증가는 앞으로 수년간의 게실염 시장 성장을 가속할 것으로 예측됩니다. 이러한 흡연 중독 증가는 적극적인 마케팅, 사회적 수용, 스트레스, 니코틴의 중독성 등의 요인에 의해 부추겨지고 있습니다. 특히 젊은이들 사이에서 사회적 영향과 동조 압력과 함께 전자 담배와 VAPE 장치를 얻을 수 있다는 것은 흡연률의 상승을 더욱 조장합니다. 흡연은 대장으로의 혈류를 손상시키고 심각한 합병증을 유발할 수 있기 때문에 게실질환의 개발 리스크의 상승으로 이어져 진단·치료 옵션 수요를 높이고 있습니다. 예를 들어, 2022년 7월 캐나다 정부 기관인 캐나다 통계국은 2021년 6월에 비해 담배 생산량이 5.8% 증가했으며 담배 총 판매량이 2022년 5월에서 1.3% 증가하여 2022년 6월에는 14억 병에 달했다고 보고했습니다. 그 결과, 흡연 중독의 만연이 게실염 시장 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Diverticulitis disease is a medical condition marked by inflammation or infection of small pouches that develop in the walls of the colon or large intestine. Symptoms may encompass lower abdominal pain, constipation, diarrhea, and rectal bleeding.

The disease is categorized into two main types sush as uncomplicated and complicated. Uncomplicated diverticulitis refers to the inflammation or infection of these small pouches, known as diverticula, within the colon walls. Various diagnostic methods such as computed tomography (CT) scans, ultrasounds, urine tests, and blood tests are employed. Treatment options encompass medications, surgery, supportive care, penicillin antibiotics, other antibiotics, dietary supplements, and intravenous (IV) fluids. These treatments are utilized by diverse end-users, including specialty centers, hospitals, and research centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diverticulitis disease market research report is one of a series of new reports from The Business Research Company that provides diverticulitis disease market statistics, including diverticulitis disease industry global market size, regional shares, competitors with a diverticulitis disease market share, detailed diverticulitis disease market segments, market trends and opportunities and any further data you may need to thrive in the diverticulitis disease industry. This diverticulitis disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diverticulitis disease market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $2.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to aging population, dietary habits, obesity, advancements in medical imaging.

The diverticulitis disease market size is expected to see strong growth in the next few years. It will grow to $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to colonoscopy and endoscopy, increased awareness, minimally invasive procedures, personalized medicine. Major trends in the forecast period include preventive measures, enhanced diagnostic tools, collaborative care models, healthcare policy changes.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. gastrointestinal care by inflating prices of laparoscopic surgical staplers and IV antibiotics imported from Italy and Croatia, resulting in delayed interventions and higher colorectal surgery expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of smoking addiction is anticipated to drive the growth of the diverticulitis disease market in the coming years. This rise in smoking addiction is fueled by factors such as aggressive marketing, social acceptance, stress, and the addictive nature of nicotine. The availability of e-cigarettes and vape devices, along with social influences and peer pressure, particularly among youth, further contributes to the rising smoking rates. Smoking is linked to an increased risk of developing diverticular disease as it impairs blood flow to the colon and can lead to severe complications, thereby elevating the demand for diagnostic and therapeutic options. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales rising by 1.3% from May 2022 to reach 1.4 billion in June 2022. Consequently, the increasing prevalence of smoking addiction is driving the growth of the diverticulitis disease market.

The rising prevalence of diabetes is also expected to propel the growth of the diverticulitis disease market. This trend is mainly driven by factors such as diets high in processed foods, sedentary lifestyles, increasing obesity rates, genetic predispositions, and an aging population. Diabetes increases the risk of complications like weakened blood vessels, making the colon more vulnerable to infections and inflammation, thus creating greater demand for treatments and therapies. For instance, in June 2024, NHS England, the UK's publicly funded healthcare system, reported that the number of individuals identified with pre-diabetes rose to 3,615,330 in 2023, marking an 18% increase from 3,065,825 in 2022. Among those under 40, cases surged nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the growing prevalence of diabetes is contributing to the expansion of the diverticulitis disease market.

Increasing healthcare expenditures are also expected to drive the growth of the diverticulitis disease market. Health expenditures encompass all costs associated with providing health services, family planning activities, nutrition programs, and emergency health assistance. A rise in healthcare spending significantly supports the development of more effective therapies and medical technologies for treating diverticulitis disease. For instance, in May 2023, the UK's Office for National Statistics reported that healthcare spending in the UK reached approximately $362.08 billion (£292 billion), reflecting a 5.6% nominal increase. Additionally, long-term health and social care expenditure grew by 2.8% in real terms in 2022. As a result, the increase in healthcare expenditure is fostering growth in the diverticulitis disease market.

Major companies operating in the diverticulitis disease market are developing innovative drugs and getting them approved to sustain their position in the market. Drug development can lead to the development of more effective treatments for diverticulitis, reducing the risk of complications and improving patient outcomes. For instance, in April 2023, the United States Food and Drug Administration, a US-based federal organization, approved Seres' microbiota drug for recurrent gut infections. This drug is designed to treat recurring gut infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst was based on a clinical trial that enrolled 346 patients with recurrent CDI. The trial found that patients who received Vowst were significantly less likely to experience a recurrence of the infection than those who received a placebo. The drug is taken orally and is based on microbiota containing Firmicutes spores, which are known to contribute to a healthy microbiome that can resist C. diff. colonization.

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diverticulitis disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diverticulitis disease market consists of revenues earned by entities by providing diagnostic services, pain management, nutritional therapy and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diverticulitis disease market also includes sales of antibiotics, dietary supplements, high-fiber foods and pain medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diverticulitis Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diverticulitis disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for diverticulitis disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diverticulitis disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Diverticulitis Disease Market Characteristics

3. Diverticulitis Disease Market Trends And Strategies

4. Diverticulitis Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Diverticulitis Disease Growth Analysis And Strategic Analysis Framework

6. Diverticulitis Disease Market Segmentation

7. Diverticulitis Disease Market Regional And Country Analysis

8. Asia-Pacific Diverticulitis Disease Market

9. China Diverticulitis Disease Market

10. India Diverticulitis Disease Market

11. Japan Diverticulitis Disease Market

12. Australia Diverticulitis Disease Market

13. Indonesia Diverticulitis Disease Market

14. South Korea Diverticulitis Disease Market

15. Western Europe Diverticulitis Disease Market

16. UK Diverticulitis Disease Market

17. Germany Diverticulitis Disease Market

18. France Diverticulitis Disease Market

19. Italy Diverticulitis Disease Market

20. Spain Diverticulitis Disease Market

21. Eastern Europe Diverticulitis Disease Market

22. Russia Diverticulitis Disease Market

23. North America Diverticulitis Disease Market

24. USA Diverticulitis Disease Market

25. Canada Diverticulitis Disease Market

26. South America Diverticulitis Disease Market

27. Brazil Diverticulitis Disease Market

28. Middle East Diverticulitis Disease Market

29. Africa Diverticulitis Disease Market

30. Diverticulitis Disease Market Competitive Landscape And Company Profiles

31. Diverticulitis Disease Market Other Major And Innovative Companies

32. Global Diverticulitis Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diverticulitis Disease Market

34. Recent Developments In The Diverticulitis Disease Market

35. Diverticulitis Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기